Neurogene Inc. (NGNE)
NGNE moved a median of 0.00% 30 minutes after news, and -0.18% by the close. How NGNE actually reacts to news — the realized, point-in-time move the market made, measured across 302 labeled events over the last three years with zero look-ahead.
NGNE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 42% | 291 |
| 30-min | 0.00% | 50% | 296 |
| 60-min | -0.13% | 47% | 302 |
| to close | -0.18% | 49% | 296 |
| Middle 50% of NGNE reactions | -1.56% to +1.88% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 302 |
Half of all Neurogene Inc. news events land between -1.56% and +1.88% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NGNE reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 32 | +0.21% | 53% | +4.45% |
| Rating reiterations | 46 | -0.74% | 35% | -1.05% |
| Price-target cuts | 10 | -0.77% | 20% | -0.98% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how NGNE ranks against every other measured name →
That’s how NGNE usually reacts — get an email when it moves on news →Email me when NGNE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NGNE's baseline. Nothing else.
Recent NGNE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.60% | -4.43% | |
| Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | -0.86% | +0.90% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.86% | +0.90% | |
| Form 10-Q Neurogene Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.33% | +1.07% | |
| Form 8-K Neurogene Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -3.29% | -1.08% | |
| Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates | Press release | Business Wire | -3.29% | -1.08% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +2.97% | +3.81% | |
| Newleos Names Rohan Palekar as Board Chairman | Press release | Business Wire | +0.00% | -3.96% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.70% | +11.55% | |
| Form 8-K Neurogene Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.53% | +3.79% | |
| Neurogene Inc. Announces Pricing of $125 Million Public Offering | Press release | Business Wire | +4.74% | +6.24% | |
| Neurogene Inc. Announces Proposed Public Offering | Press release | Business Wire | +4.74% | +6.24% | |
| Form 8-K Neurogene Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.83% | -0.19% | |
| Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome | Press release | Business Wire | +0.83% | -0.19% | |
| Form 8-K Neurogene Inc. For: Jun 08 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | +5.54% | |
| Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome | Press release | Business Wire | -0.50% | +5.54% | |
| Form 8-K Neurogene Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -2.37% | -3.60% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.22% | -2.49% | |
| Form 10-Q Neurogene Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.01% | +3.42% | |
| Form 8-K Neurogene Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +2.01% | +3.42% | |
| Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy | Press release | Business Wire | +0.00% | +2.87% | |
| Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates | Press release | Business Wire | +2.01% | +3.42% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.54% | -3.22% | |
| Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy | Press release | Business Wire | +0.62% | +0.15% | |
| Form 8-K Neurogene Inc. For: Apr 20 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +0.51% | |
| Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors | Press release | Business Wire | -0.40% | +0.51% | |
| Form ARS Neurogene Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +3.02% | +6.34% | |
| Form DEF 14A Neurogene Inc. For: Jun 03 | SEC filing · Form DEF | SEC EDGAR | +3.02% | +6.34% | |
| Form DEFA14A Neurogene Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +3.02% | +6.34% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -1.78% | -1.02% | |
| Form 10-K Neurogene Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.18% | +3.72% | |
| Form 8-K Neurogene Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -0.21% | +8.29% | |
| Form S-8 Neurogene Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.18% | +3.72% | |
| Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates | Press release | Business Wire | -0.21% | +8.29% | |
| Neurogene to Participate in Stifel 2026 Virtual CNS Forum | Press release | Business Wire | +1.51% | +2.13% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.74% | +7.75% | |
| Form 8-K Neurogene Inc. For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | +2.31% | |
| Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome | Press release | Business Wire | -1.05% | +2.31% | |
| Neurogene to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.29% | -4.71% | |
| Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.29% | -4.71% | |
| Form 8-K Neurogene Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -3.83% | -4.11% | |
| Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome | Press release | Business Wire | -3.83% | -4.11% | |
| Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.22% | -9.08% | |
| Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.32% | -4.25% | |
| Form 8-K Neurogene Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -2.05% | — | |
| Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome | Press release | Business Wire | -2.05% | — | |
| Form 8-K Neurogene Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | -3.89% | |
| Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome | Press release | Business Wire | +0.02% | -3.89% | |
| Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.02% | -3.89% | |
| Form 8-K Neurogene Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | +1.88% | +18.56% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NGNE section they belong to.
Where else NGNE is measured.
NGNE earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Neurogene Inc.'s median reaction calculated?
Every labeled NGNE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 302 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of NGNE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NGNE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.